Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs is a promising company with a long-term focus on the development of novel vaccines and immunotherapies. While their GEO-MVA program has potential, their Phase 3 immunobridging study is not expected to take place until Q4 2026, making the MPOX opportunity less likely to provide immediate stock price support. Additionally, their previous efforts in the COVID vaccine market have not resulted in significant commercial success, indicating a need for further developments in this area.

Geovax Labs is facing financial difficulties as seen by their drastic decrease in revenue due to a contract termination and low cash balance. While their pipeline offers some potential, it is secondary to their main program, GEO-MVA, and may not be enough to drive significant value for investors. Additionally, a recent reverse stock split could signal weakness in the company's stock and pose a risk for future dilution for investors. Even with potential catalysts in clinical execution and oncology strategy, the extended timelines may not provide significant impact in the near term.